Top Markets
Coin of the day
Peak Bio, Inc. Peak Bio, Inc.

Peak Bio, Inc.

PKBO
Rank in Stocks #37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Share Price
$0.07
Last synced: 2024-11-12
Market Cap
$1.62M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Peak Bio, Inc. (PKBO)

Category

EPS for Peak Bio, Inc. (PKBO)
EPS as of 2026 TTM: 0
According to Peak Bio, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Peak Bio, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE